

INFORMATION DISCLOSURE STATEMENT


Applicant : Andersson, et al.
 App. No : 10/802,970
 Filed : March 16, 2004
 For : AZACYCLIC COMPOUNDS
 Examiner : Johnson, J.H.
 Art Unit : 1624

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 27, 2006

(Date)


Sam K. Tahmassebi, Reg. No. 45,151

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 29 references to be considered by the Examiner. Also enclosed are 26 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 27, 2006

By: 

Sam K. Tahmassebi
 Registration No. 45,151
 Attorney of Record
 Customer No. 20,995
 (619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802970
		Filing Date	March 16, 2004
		First Named Inventor	Andersson, et al.
		Art Unit	1624
(Multiple sheets used when necessary)		Examiner	Johnson, J.
SHEET 1 OF 2		Attorney Docket No.	ACADIA.014C2



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,707,798	01/13/1998	Brann, Mark	
	2	5,216,165	06/01/1993	Mobilio, et al.	
	3	2004/0006081 A1	01/08/2004	Burrows, et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	4	Mouliigner, Rev. Neurol. 150: 3-15 (1994). (Abstract)	
	5	Fuller, <i>Biology of Serotonergic Transmission</i> , 1982.	
	6	Boullin, <i>Sertotonin In Mental Abnormalites</i> 1: 316 (1978)	
	7	Gershon, et al. <i>The Peripheral Actions of 5-Hydroxytryptamine</i> , 246, (1989)	
	8	Saxena, et al. <i>J. Cardiovascular Pharmacol.</i> 15 supp. 7 (1990)	
	9	Meltzer, <i>Neuropsychopharmacology</i> 21: 106S-115S (1999)	
	10	Barnes & Sharp, <i>Neuropharmacology</i> , 38: 1083-1152 (1999)	
	11	Glennon, <i>Nerosci Biobehavioral Rev.</i> 14:35 (1990)	
	12	Barr & Manning, <i>J. Biol. Chem.</i> 272, 32979-87 (1997)	
	13	Cerione et al., <i>Biochemistry</i> 23: 4519-25 (1984)	
	14	Bond, et al. <i>Nature</i> , 374: 272 (1995)	
	15	Saltzman, et al. <i>Biochem. Biophys. Res. Comm.</i> 181: 1469-1478	
	16	Julius et al. <i>Proc. Natl. Acad. Sci. USA</i> , 87: 928-932.	
	17	Pace, et al. <i>Proc. Natl. Acad. Sci. USA</i> , 88: 7031-7035 (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802970
		Filing Date	March 16, 2004
		First Named Inventor	Andersson, et al.
		Art Unit	1624
(Multiple sheets used when necessary)		Examiner	Johnson, J.
SHEET 2 OF 2		Attorney Docket No.	ACADIA.014C2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	18	Vallar, et al. <i>Nature</i> , 330: 556-558 (1987)	
	19	Eichelbaum, <i>Clin. Exp. Pharmacol. Physio.</i> , 23:983-985 (1996)	
	20	Linder, <i>Clin. Chem.</i> 43: 254-66- (1997)	
	21	Lowe, et al. <i>J. Med. Chem.</i> 37: 2831-40 (1994)	
	22	Carroll, et al., <i>J. Med. Chem.</i> 35: 2184-91 (1992)	
	23	Varma et al., <i>Org. Lett.</i> 1: 697-700 (1999)	
	24	Cherkasov, et al. <i>Tetrahedron</i> 41: 2567 (1985).	
	25	Scheibye, et al. <i>Bull. Soc. Chim. Belg.</i> 87:229 (1978)	
	26	Kuehne et al. <i>J. Org. Chem.</i> 56: 2701 (1991)	
	27	Kuehne, et al. <i>J. Org. Chem.</i> (1991) 56:513	
	28	Mansbach, et al., <i>Psychopharmacology</i> 94 507-514 (1988)	
	29	Bakshi, et al., <i>J. Pharmacol. Exp. Ther.</i> 271: 787-94)	

2463622
032106

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.